Progress and prospects for treating ataxia telangiectasia

References

• Chessa L, Polizzi A, Ruggieri M. Ataxia-telangiectasia. In: Ruggieri M, Pascual-Castroviejo I, Di Rocco C, editors. Neurocutaneous diseases. Phakomatoses and hamartoneoplastic syndromes. Wien/New York: Springer-Verlag; 2008. p. 731–758.
   Google Scholar
• Rothblum-Oviatt C, Wright J, Lefton-Greif MA, et al. Ataxia telangiectasia: a review. Orph J Rare Dis. 2016;11:159.
   PubMed Web of Science ®Google Scholar
• Savitsky K, Bar-Shira A, Gilad S, et al. A single Ataxia Telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268:1749–1753.
   PubMed Web of Science ®Google Scholar
• Abraham RT. Phosphatidylinositol 3-kinase related kinases. Curr Opin Immunol. 1996;8:412–418.
   PubMed Web of Science ®Google Scholar
• Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol. 2013;14:197–210.
   Web of Science ®Google Scholar
• Shiloh Y. ATM: expanding roles as a chief guardian of genome stability. Exp Cell Res. 2014;329:154–161.
   PubMed Web of Science ®Google Scholar
• Shiloh Y, Lederman HM. Ataxia-telangiectasia (A-T): an emerging dimension of premature ageing. Ageing Res Rev. 2017;33:76–88.
   PubMed Web of Science ®Google Scholar
• Choy KR, Watters DJ. Neurodegeneration in Ataxia-Telangiectasia: multiple roles of ATM kinase in cellular homeostasis. Dev Dynam. 2018;247:33–46.
   PubMed Web of Science ®Google Scholar
• Boder E. Ataxia-telangiectasia. In: Gomez MR (ed.) Neurocutaneous Diseases. A Practical Approach. Boston: Butterworths. 1987:95–117.
   Google Scholar
• Syllaba L, Henner K. Contribution à l’indépendence de l’athétose double idiopathique et congénitale. Rev Neurol. 1926;1:541–562.
   Google Scholar
• Coon EA, Koehler PJ, Boes CJ. Denise Louis-Bar: the eponymous woman of Louis-Bar syndrome. Neurology. 2018;91:75–79.
   Web of Science ®Google Scholar
• Louis-Bar D. Sur un syndrome progressif comprenant des télangiectasies capillaries cutnées et conjonctivales symetrique naevoide et de troubles cerebellaux. Confin Neurol (Basel). 1941;4:432–442.
   Google Scholar
• Swift M, Morrell D, Cromartie E, et al. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet. 1986;39:573–583.
   PubMed Web of Science ®Google Scholar
• van Os NJ, Roeleveld N, Weemaes CM, et al. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet. 2016;90:105–117.
   PubMed Web of Science ®Google Scholar
• Chessa L. Current and future therapeutic strategies to treat ataxia telangiectasia. Curr Opin Orphan Drugs. 2014;2:877–887.
   Web of Science ®Google Scholar
• Carranza D, Torres-Rusillo S, Ceballos-Pérez G, et al. Reconstitution of the Ataxia-Telangiectasia cellular phenotype with lentiviral vectors. Front Immunol. 2018;9:2703.
   PubMed Web of Science ®Google Scholar
• Woelke S, Pommerening H, Kieslich M, et al. Growth hormone treatment in patients with ataxia telangiectasia. Growth Factors. 2017;35:125–130.
   PubMed Web of Science ®Google Scholar
• Hui CW, Song X, Ma F, et al. Ibuprofen prevents progression of ataxia telangiectasia symptoms in ATM-deficient mice. J Neuroinflammation. 2018;15:308.
   PubMed Web of Science ®Google Scholar
• Nissenkorn A, Hassin-Baer S, Lerman SF, et al. Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate. J Child Neurol. 2013;28:155–160.
   PubMed Web of Science ®Google Scholar
• Chessa L, Leuzzi V, Plebani A, et al. Intra-Erythrocyte infusion of dexamethasone reduces neurological symptoms in Ataxia Teleangiectasia patients: results of a phase 2 trial. Orph J Rare Dis. 2014;9:5.
   PubMed Web of Science ®Google Scholar
• Chen J, Chen Y, Vail G, et al. The impact of glutamine supplementation on the symptoms of ataxia-telangiectasia: a preclinical assessment. Mol Neurodegener. 2016;11:60.
   PubMed Web of Science ®Google Scholar
• Fang EF, Kassahun H, Croteau DL, et al. NAD+ replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 2016;24:566–581.
   PubMed Web of Science ®Google Scholar
• Woelke S, Valesky E, Bakhtiar S, et al. Treatment of granulomas in patients with Ataxia Telangiectasia. Front Immunol. 2018;9:2000.
   PubMed Web of Science ®Google Scholar
• Slack J, Albert MH, Balashov D, et al. Outcome of hematopoietic cell transplantation for DNA double- strand break repair disorders. J Allergy Clin Immunol. 2018;141:322–328.
   PubMed Web of Science ®Google Scholar
• Dillon MT, Boylan Z, Smith D, et al. PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. Clin Transl Radiat Oncol. 2018;12:16–20.
   PubMed Web of Science ®Google Scholar
• Georgiev D, Mehta D, Zacharia A, et al. Bilateral deep brain stimulation of the globus pallidus pars interna in a patient with variantAtaxia-Telangiectasia. Mov Disord Clin Pract. 2019;3:405–408.
   Google Scholar
• Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, et al. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr. 2004;144:505–511.
   PubMed Web of Science ®Google Scholar
• Verhagen MM, Abdo WF, Willemsen MA, et al. Clinical spectrum of ataxia-telangiectasia in adulthood. Neurology. 2009;73:430–437.
   PubMed Web of Science ®Google Scholar
• van Os NJH, Haaxma CA, van der Flier M, et al. Ataxia-telangiectasia: recommendations for multidisciplinary treatment. Dev Med Child Neurol. 2017;7:680–689.
   Google Scholar
• Schroeder SA, Swift M, Sandoval C, et al. Interstitial lung disease in patients with ataxia-telangiectasia. Pediatr Pulmonol. 2005;39:537–543.
   PubMed Web of Science ®Google Scholar
• Bhatt JM, Bush A, van Gerven M, et al. ERS statement on the multidisciplinary respiratory management of ataxia telangiectasia. Eur Respir Rev. 2015;24:565–581.
   PubMed Web of Science ®Google Scholar
• Schroeder SA, Zielen S. Infections of the respiratory system in patients with ataxia-telangiectasia. Pediatr Pulmonol. 2014;49:389–399.
   PubMed Web of Science ®Google Scholar
• McGrath-Morrow SA, Lederman HM, Aherrera AD, et al. Pulmonary function in children and young adults with ataxia telangiectasia. Pediatr Pulmonol. 2014;49:84–90.
   PubMed Web of Science ®Google Scholar
• Voss S, Pietzner J, Hoche F, et al. Growth retardation and growth hormone deficiency in patients with Ataxia telangiectasia. Growth Factors. 2014;32:123–129.
   PubMed Web of Science ®Google Scholar
• Ehlayel M, Soliman A, De Sanctis V. Linear growth and endocrine function in children with ataxia telangiectasia. Indian J Endocrinol Metab. 2014;1:S93–6.
   Google Scholar
• Pommerining H, Van Dullemen S, Kieslich M, et al. Body composition, muscle strength and hormonal status in patients with ataxia telangiectasia: a cohort study. Orphanet J Rare Dis. 2015;10:155.
   PubMed Web of Science ®Google Scholar
• Ross LJ, Capra S, Baguley B, et al. Nutritional status of patients with Ataxia Telangiectasia: a case for early and ongoiong nutrition support and intervention. J Paediatr Child Health. 2015;51:802–807.
   PubMed Web of Science ®Google Scholar
• Nissenkorn A, Levy-Shraga Y, Banet-Levi Y, et al. Endocrine abnormalities in Ataxia Telangiectasia: findings from a national cohort. Pediatr Res. 2016;79:889–894.
   PubMed Web of Science ®Google Scholar
• Stewart E, Prayle AP, Tooke A, et al. Growth and nutrition in children with ataxia telangiectasia. Arch Dis Child. 2017;101:1137–1141.
   Web of Science ®Google Scholar
• Peretz S, Jensen R, Baserga R, et al. ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Pnas. 2001;98:1676–1681.
   PubMed Web of Science ®Google Scholar
• Krauthammer A, Lahad A, Sarouk Y, et al. Long-term nutritional and gastrointestinal aspects in patients with ataxia telangiectasia. Nutrition. 2018;46:48–52.
   PubMed Web of Science ®Google Scholar
• O’Driscoll M. Mouse models for ATR deficiency. DNA Repair (Amst). 2009;8:1333–1337.
   PubMed Web of Science ®Google Scholar
• Barlow C, Hirotsune S, Paylor R, et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell. 1996;86:159–171.
   PubMed Web of Science ®Google Scholar
• Alba-Betancourt C, Luna-Acosta JL, Ramírez-Martínez CE, et al. Neuro-protective effects of growth hormone (GH) after hypoxia-ischemia injury in embryonic chicken cerebellum. Gen Comp Endocrinol. 2013;183:17–31.
   PubMed Web of Science ®Google Scholar
• Liu JP, Baker J, Perkins AS, et al. Mice carrying null mutations of the genes encoding insulin-like growth factor-I (IGF-1) and type-1 IGF receptor. Cells. 1993;75:59–72.
   PubMed Web of Science ®Google Scholar
• Morrione A, Navarro M, Romano G, et al. The role of the insulin receptor substrate-1 in the differentiation of rat hippocampal neuronal cells. Oncogene. 2001;20:4842–4852.
   PubMed Web of Science ®Google Scholar
• Pierotti MA, Berrino F, Gariboldi M, et al. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene. 2013;32:1475–1487.
   PubMed Web of Science ®Google Scholar
• Andrade IG, Costa-Carvalho BT, Da Silva R, et al. Risk of atherosclerosis in patients with Ataxia Telangiectasia. Ann Nutr Metab. 2015;66:196–201.
   PubMed Web of Science ®Google Scholar
• Wu D, Yang H, Xiang W, et al. Heterozygous mutation of Ataxia Telangiectasia mutated gene aggravates hypercholesterolemia in apoE-deficient mice. J Lipid Res. 2005;46:1380–1387.
   PubMed Web of Science ®Google Scholar
• Mercer JR, Cheng KK, Figg N, et al. DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circ Res. 2015;107:1021–1031.
   Google Scholar
• Yu E, Calvert PA, Mercer JR, et al. DNA damage can promote atherosclerosis independently of reactive oxygen species thorough effects on smooths muscle cells and monocytes and correlates with higher-risk plaques in humans. Circulation. 2013;128:702–712.
   PubMed Web of Science ®Google Scholar
• Blignaut M, Loos B, Botchway SW, et al. Ataxia-Telangiectasia mutated is located in cardiac mithochondria and impacts oxidative phosphorylation. Sci Rep. 2019;9:4782.
   PubMed Web of Science ®Google Scholar
• Paulino TL, Rafael MN, Hix S, et al. Is age a risk factor for liver disease and metabolic alterations in ataxia Telangiectasia patients? Orph J Rare Dis. 2017;12:136.
   PubMed Web of Science ®Google Scholar
• Ruggieri M, Arcidiacono G, Tinè A, et al. Pulmonary valve stenosis in a patient with ataxia telangiectasia. Eur Heart J. 1996;17:968.
   PubMed Web of Science ®Google Scholar
• Ziv S, Brenner O, Smorodinsky NI, et al. Impaired genomic stability and increased oxidative stress exacerbate different features of Ataxia-telangiectasia. Hum Mol Genet. 2005;14:2929–2953.
   PubMed Web of Science ®Google Scholar
• Reichenbach J, Schubert R, Schindler D, et al. Elevated oxidative stress in patients with ataxia telangiectasia. Antioxid Redox Signal. 2002;4:465–469.
   PubMed Web of Science ®Google Scholar
• Maciejczyk M, Mikoluc B, Pietrucha B, et al. Oxidative stress, mitochondrial abnormalities and antioxidant defense in Ataxia Telangiectasia, bloom syndrome and nijmegen breakage syndrome. Redox Biol. 2017;11:375.
   PubMed Web of Science ®Google Scholar
• Da Silva R, Dos Santos-Valente EC, Burim Scomparini F, et al. The relationship between nutritional status, vitamin A and zinc levels and oxidative stress in patients with ataxia-telangiectasia. Allergol Immunopathol (Madr). 2014;42:329–335.
   PubMed Web of Science ®Google Scholar
• Squadrone S, Brizio P, Mancini C, et al. Blood metal levels and related antioxidant enzyme activities in patients with ataxia telangiectasia. Neurobiol Dis. 2015;81:162–167.
   PubMed Web of Science ®Google Scholar
• Pietrucha B, Heropolitanska-Pliszka E, et al. Comparison of selected parameters of redox homeostasis in patients with Ataxia-Telangiectasia and Nijmegen breakage syndrome. Oxid Med Cell Longev. 2017;2017:6745840.
   PubMedGoogle Scholar
• Reliene R, Schiestl RH. Experimental antioxidant therapy in ataxia telangiectasia. Clin Med Oncol. 2008;2:431–436.
   PubMedGoogle Scholar
• Chen J, Herrup K. Glutamine acts as a neuroprotectant against DNA damage, beta-amyloid and H2O2-induced stress. PLoS One. 2012;7:e33177.
   PubMed Web of Science ®Google Scholar
• Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123:3678–3684.
   PubMed Web of Science ®Google Scholar
• Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37(Suppl 1):81–84.
   PubMedGoogle Scholar
• Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int. 2017;37(Suppl 1):85–89.
   PubMedGoogle Scholar
• Yu J, Marsh S, Hu J, et al. The pathogenesis of non-alcoholic fatty liver disease: interplay between diet, gut microbiota and genetic background. Gastroenterol Res Pract. 2016;2016:2862173.
   PubMed Web of Science ®Google Scholar
• Caballero T, Caba-Molina M, Salmeron J, et al. Non-alcoholic steatohepatitis in a patient with Ataxia Telangiectasia. Case Reports Hepatol. 2014;2014:761250.
   PubMedGoogle Scholar
• Weiss B, Krauthammer A, Soudack M, et al. Liver disease in pediatric patients with Ataxia Telangiectasia: a novel report. J Pediatr Gastroenterol Nutr. 2016;62:550–555.
   PubMed Web of Science ®Google Scholar
• Daugherity E, Balmus G, Al Saei A, et al. The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease. Cell Cycle. 2012;10:1918–1928.
   Google Scholar
• Strich SJ. Pathological findings in three cases of Ataxia Telangiectasia. J Neurol Neurosur Psychiat. 1966;29:489–499.
   Web of Science ®Google Scholar
• Ajmera V, Loomba R. Can elastography differentiate isolated fatty liver from non-alcoholic steatohepatitis? Semin Liver Dis. 2018;38:14–20.
   PubMed Web of Science ®Google Scholar
• Ichikawa S, Motosugi U, Morisaka H, et al. Comparison of the diagnostic accuracies of magnetic resonance elastography and transient elastography for hepatic fibrosis. Magn Reason Imaging. 2015;33:26–30.
   PubMed Web of Science ®Google Scholar
• Han MA, Saouaf R, Ayoub W, et al. Magnetic resonance imaging and transient elastography in the management of non-alcoholic fatty liver disease (NAFLD). Expert Rev Clin Pharmacol. 2017;10:379–390.
   PubMed Web of Science ®Google Scholar
• Hwang J-Y, Yoon HM, Kim JR, et al. Diagnostic performance of transient elastography for liver fibrosis in children: a systematic review and meta-analysis. Am J Roentgenol. 2018;211:W257–66.
   PubMed Web of Science ®Google Scholar
• Lugrin J, Rosenblatt-Velin N, Parrapanov R. Liaudet L The role of oxidative stress during inflammatory processes. Biol Chem. 2014;395:203–230.
   PubMed Web of Science ®Google Scholar
• Zaki-Dizaji M, Akrami SM, Azizi G, et al. Inflammation, a significant player of ataxia telangiectasia pathogenesis? Inflamm Res. 2018;67:559–570.
   PubMed Web of Science ®Google Scholar
• Yang Y, Hui CW, Li J, et al. The interaction of the atm genotype with inflammation and oxidative stress. PLoS One. 2014;9:e85863.
   PubMed Web of Science ®Google Scholar
• Duecker R, Baer P, Eickmeier O, et al. Oxidative stress-drive pulmonary inflammation and fibrosis in a mouse model of human ataxia telangiectasia. Redox Biol. 2018;14:645–655.
   PubMed Web of Science ®Google Scholar
• McGrath-Morrow SA, Collaco JM, Detrick B, et al. Serum interleukin-6 levels and pulmonary function in Ataxia-Telangiectasia. J Pediatr. 2016;171:256–261.
   PubMed Web of Science ®Google Scholar
• McGrath-Morrow SA, Collaco JM, Crawford TO, et al. Elevated serum IL-8 levels in Ataxia Telangiectasia. J Pediatr. 2010;156:682–684.
   PubMed Web of Science ®Google Scholar
• McGrath-Morrow SA, Ndeh R, Collaco J, et al. Inflammation and transcriptional responses of peripheral blood mononuclear cells in classic ataxia telangiectasia. PLoS One. 2018;13:e0209496.
   PubMed Web of Science ®Google Scholar
• Paller AS, Massey RB, Curtis MA, et al. Cutaneous granulomatous lesions in patients with ataxia-telangiectasia. J Pediatr. 1991;119:917–922.
   PubMed Web of Science ®Google Scholar
• Cantarutti N, Claps A, Angelino G, et al. Multi-drugs resistant acne rosacea in a child affected by Ataxia-Telangiectasia: successful treatment with Isotretinoin. Ital J Pediatr. 2015;41:23.
   PubMed Web of Science ®Google Scholar
• Mitra A, Gooi J, Darling J, et al. Infliximab in the treatment of a child with cutaneous granulomas associated with ataxia telangiectasia. J Am Acad Dermatol. 2011;65:676–677.
   PubMed Web of Science ®Google Scholar
• Privette ED, Ram G, Treat JR, et al. Healing of granulomatous skin changes in ataxia-telangiectasia after treatment with intravenous immunoglobulin and topical mometasone 0.1% ointment. Pediatr Dermatol. 2014;31:703–707.
   PubMed Web of Science ®Google Scholar
• Bagley J, Cortes ML, Breakefield XO, et al. Bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice. Blood. 2004;104:572–578.
   PubMed Web of Science ®Google Scholar
• Blau HM, Daley GD. Stem cells in the treatment of disease. N Engl J Med. 2019;380:1748–1760.
   PubMed Web of Science ®Google Scholar
• Pietzner J, Baer PC, Duecker RP, et al. Bone marrow transplantation improves the outcome of Atm-deficient mice through the migration of ATM- competent cells. Hum Mol Genet. 2013;22:493–507.
   PubMed Web of Science ®Google Scholar
• Bakhtiar S, Woelke S, Huenecke S, et al. Pre-emptive allogeneic hematopoietic stem cell transplantation in Ataxia Telangiectasia. Front Immunol. 2018;9:2495.
   PubMed Web of Science ®Google Scholar
• Ussowicz M, Musiał J, Duszenko E, et al. Long-term survival after allogeneic-matched sibling PBSC transplantation with conditioning consisting of low-dose busilvex and fludarabine in a 3-year-old boy with ataxia-telangiectasia syndrome and ALL. Bone Marrow Transplant. 2013;48:740–741.
   PubMed Web of Science ®Google Scholar
• Beier R, Sykora KW, Woessmann W, et al. Allogeneic-matched sibling stem cell transplantation in a 13- year-old boy with ataxia telangiectasia and EBV-positive non-Hodgkin lymphoma. Bone Marrow Transplant. 2016;51:1271–1274.
   PubMed Web of Science ®Google Scholar
• Bhatt N, Ghosh R, Roy S, et al. Robust reprogramming of Ataxia-Telangiectasia patient and carrier erythroid cells to induced pluripotent stem cells. Stem Cell Res. 2016;17:296–305.
   PubMed Web of Science ®Google Scholar
• Lecona E, Fernandez-Capetillo O. Targeting ATR in cancer. Nat Rev Cancer. 2018;18:586–595.
   PubMed Web of Science ®Google Scholar
• Ussowicz M, Wawrzyniak-Dzierżek E, et al. Allogeneic stem cell transplantation after fanconi anemia conditioning in children with Ataxia-Telangiectasia results in stable T cell engraftment and lack of infections despite mixed chimerism. Biol Blood Marrow Transplant. 2018;24:2245–2249.
   PubMed Web of Science ®Google Scholar
• Lavin MF. The appropriateness of the mouse model for ataxia-telangiectasia: neurological defects but no neurodegener- ation. DNA Repair (Amst). 2013;12:612–619.
   PubMed Web of Science ®Google Scholar
• Daniel JA, Pellegrini M, Lee BS, et al. Loss of ATM kinase activity leads to embryonic lethality in mice. J Cell Biol. 2012;198:295.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Wang Y, Jiang W, et al. Kinase-dead ATM protein causes genomic instability and early embryonic lethality in mice. J Cell Biol. 2012;198:305–313.
   PubMed Web of Science ®Google Scholar
• Quek H, Luff J, Cheung K, et al. A rat model of ataxia- telangiectasia: evidence for a neurodegenerative phenotype. Hum Mol Genet. 2017;26:109–123.
   PubMed Web of Science ®Google Scholar
• Quek H, Luff J, Cheung K, et al. Rats with a missense mutation in Atm display neuroinflammation and neurodegenera- tion subsequent to accumulation of cytosolic DNA following unrepaired DNA damage. J Leukoc Biol. 2017;101:927–947.
   PubMed Web of Science ®Google Scholar
• Gueven N, Luff J, Peng C, et al. Dramatic extension of tumor latency and correction of neurobehavioral phenotype in Atm-mutant mice with a nitroxide antioxidant. Free Radic Biol Med. 2006;41:992–1000.
   PubMed Web of Science ®Google Scholar
• D’Souza A, Parish IA, Krause DS, et al. Reducing mitochondrial ROS improves disease-related pathol- ogy in a mouse model of ataxia-telangiectasia. Mol Ther. 2013;21:42–48.
   PubMed Web of Science ®Google Scholar
• Meshulam L, Galron R, Kanner S, et al. The role of the neuro- astro-vascular unit in the etiology of ataxia telangiectasia. Front Pharmacol. 2012;3:157.
   PubMed Web of Science ®Google Scholar
• Buoni S, Zannolli R, Sorrentino L, et al. Betamethasone and improvement of neurological symptoms in ataxia-telangiectasia. Arch Neurol. 2006;63:1479–1482.
   PubMedGoogle Scholar
• Broccoletti T, Del Giudice E, Amorosi S, et al. Steroid-induced improvement of neurological signs in ataxia-telangiectasia patients. Eur J Neurol. 2008;15:223–228.
   PubMed Web of Science ®Google Scholar
• Broccoletti T, Del Giudice E, Cirillo E, et al. Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia. Eur J Neurol. 2011;18:564–570.
   PubMed Web of Science ®Google Scholar
• Russo I, Cosentino C, Del Giudice E, et al. In ataxia-telangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity. Eur J Neurol. 2009;16:755–759.
   PubMed Web of Science ®Google Scholar
• Cirillo E, Del Giudice E, Micheli R, et al. Minimum effective betamethasone dosage on the neurological phenotype in patients with ataxia-telangiectasia: a multicenter observer-blind study. Eur J Neurol. 2018;25:833–840.
   PubMed Web of Science ®Google Scholar
• Zannolli R, Buoni S, Betti G, et al. A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Mov Disord. 2012;27:1312–1316.
   PubMed Web of Science ®Google Scholar
• Magnani M, Rossi L. Approaches to erythrocyte-mediated drug delivery. Expert Opin Drug Deliv. 2014;11:677–687.
   PubMed Web of Science ®Google Scholar
• Leuzzi V, Micheli R, D’Agnano D, et al. Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia. Neurol Neuroimmunol Neuroinflamm. 2015;2:e98.
   PubMed Web of Science ®Google Scholar
• Menotta M, Biagiotti S, Bianchi M, et al. Dexamethasone partially rescues ATM deficiency in Ataxia Telangiectasia by promoting a shortened ATM variant retaining kinase activity. J Biol Chem. 2012;287:41352–41363.
   PubMed Web of Science ®Google Scholar
• Biagiotti S, Menotta M, Orazi S, et al. Dexamethasone improves redox state in ataxia telangiectasia cells by promoting an NRF2-mediated antioxidant response. Febs J. 2016;283:3962–3978.
   PubMed Web of Science ®Google Scholar
• Menotta M, Biagiotti S, Bartolini G, et al. Nano-mechanical characterization of Ataxia Telangiectasia cells treated with dexamethasone. Cell Biochem Biophys. 2017;75:95–102.
   PubMed Web of Science ®Google Scholar
• Menotta M, Orazi S, Gioacchini AM, et al. Proteomics and transcritomics analyses of ataxia telangiectasia cells treated with Dexamethasone. PLoS One. 2018;13:e0195388.
   PubMed Web of Science ®Google Scholar
• Li J, Chen J, Ricupero CL, et al. Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia-telangiectasia. Nat Med. 2012;18:783–790.
   PubMed Web of Science ®Google Scholar
• Li J, Hart RP, Mallimo EM, et al. EZH2-mediated H3K27 trimethylation mediates neurodegeneration in ataxia-telangiectasia. Nat Neurosci. 2013;16:1745–1753.
   PubMed Web of Science ®Google Scholar
• Di Siena S, Campolo F, Gimmelli R, et al. Atm reactivation reverses ataxia telangiectasia phenotypes in vivo. Cell Death Dis. 2018;9:314.
   PubMed Web of Science ®Google Scholar
• Hoche F, Daly MP, Chutake YK, et al. The cerebellar cognitive affective syndrome in Ataxia-Telangiectasia. Cerebellum. 2019;18:225–244.
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA1, Greenstein PE, Sullivan KL, et al. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellarataxia type 3. Neurology. 2012;78:545–550.
   PubMed Web of Science ®Google Scholar
• Romano S, Coarelli G, Marcotulli C, et al. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14:985–991.
   PubMed Web of Science ®Google Scholar
• Feil K, Adrion C, Teufel J, et al. Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial. BMC Neurol. 2017;17:7.
   PubMed Web of Science ®Google Scholar